UNITED NATIONS POPULATION INFORMATION NETWORK (POPIN)
UN Population Division, Department of Economic and Social Affairs,
with support from the UN Population Fund (UNFPA)

Reducing the HIV risk from mother to infant

Network, vol. 17(2) Winter 1997: Family Planning and AIDS Prevention: 

Maximizing Reproductive Health Resources







Copyright 1997, Family Health International







Reducing the HIV Risk From Mother to Infant





HIV transmission can occur in utero, during birth or from

breastfeeding.





Between one-fourth and one-third of infants born to women infected

with HIV worldwide become infected themselves.1 Called "vertical" or

"perinatal" transmission, passing this infection from mother to child

is the primary means by which infants acquire HIV.Most pregnant women

with HIV have been infected through unprotected intercourse.

Consequently, providers should recognize that promoting HIV

prevention among women is the primary means of preventing HIV

infections among infants. For those women who do become infected,

preventing pregnancy is a secondary way of reducing the spread of HIV

to infants.



Although it is clear that infections can occur in utero, during birth

or through breastmilk, researchers are not sure about the relative

risk associated with each phase.



"In the future, new research findings may affect recommendations to

help HIV infected pregnant women protect their offspring from HIV,"

says Elizabeth Preble of FHI's AIDS Control and Prevention (AIDSCAP)

Project. "In the meantime, however, policy-makers should understand

that our current knowledge about HIV transmission to infants involves

complex issues such as breastfeeding versus bottlefeeding, voluntary

and available HIV testing, and other issues." Preble is drafting

guidelines for the World Health Organization (WHO) on STD prevention

in the maternal and child health/family planning setting.



Pregnancy and delivery



During pregnancy, the stage of maternal infection can affect

perinatal transmission rates. The greater the progression of disease

in the mother, as measured by viral load or CD4 cell counts, the more

likely is transmission. Other factors that may increase the risk

include hemorrhage during labor, vaginal delivery, duration of labor

after the rupture of membranes, and some obstetrical approaches.

Amniocentesis or other invasive procedures before labor are also

factors that may increase the risk.2  In 1994, a clinical trial

showed that drug therapy with zidovudine, or AZT, decreased

transmission from pregnant mother to newborn. AZT was given to women

after their first trimester of pregnancy, intravenously during labor

and delivery, and was given to their infants for the first six weeks

of their lives.3 In countries where AZT is available, AZT therapy

increased dramatically after the report.In a follow-up study of 103

infants whose infected mothers received AZT therapy and 453 infants

whose mothers did not, HIV transmission was 19 percent among those

not using AZT but only 8 percent among those receiving therapy.4 

Currently, the cost of drugs such as AZT is prohibitively expensive

in most developing countries. Studies are testing new drugs and

simpler regimens that may curtail transmission at lower cost.(In

January, a U.S. National Institutes of Health advisory panel

recommended that infected mothers should continue taking AZT to

reduce chances of infecting their babies, despite a National Cancer

Institute study that raises questions about whether the drug may

increase cancer risks. The study found high doses of AZT increased

lung, liver and skin cancers in baby mice. However, there is no

evidence of any human child getting cancer after AZT treatment, and

a study by the manufacturer of AZT found no risk among mice from

lower doses that would be equivalent to those given pregnant women.)



Other research is testing treatments with a specially made

immunoglobulin, which contains antibodies to HIV. This immunoglobulin

comes from infected individuals, but it has been carefully treated

to kill HIV and other infectious agents. It theoretically should

boost the immune systems of pregnant mothers and infants, so that the

virus is less likely to be transmitted from mother to child.



Some studies have suggested that cesarean section delivery in

HIV-infected mothers can have a protective effect by avoiding passage

through the birth canal, where there is contact with infected

maternal blood and cervical fluids. However, study results are

inconclusive.



Moreover, cesarean births, especially in developing countries, have

a relatively high risk of postoperative mortality. Two recent studies

provide some evidence that complications of a cesarean section are

common among HIV-positive women, particularly those who have severely

suppressed immune systems.5  Obstetrical interventions that could

increase the risk of HIV transmission should be avoided. The rupture

of membranes for more than four hours prior to delivery may be

associated with increased risk of HIV infection, so intentionally

rupturing the membranes to induce or accelerate labor should be

avoided.6 Also, placing internal fetal-scalp electrodes should be

avoided when labor can be managed safely with external fetal

monitoring.7  Other types of interventions under consideration are

disinfecting the birth canal of HIV-infected women and using vitamin

A. A recent study using chlorhexidine to wash the birth canals of

HIV-infected women in Malawi did not reduce the transmission rate

except among those whose membranes were ruptured more than four hours

before delivery.8 Another Malawi study suggested that maternal

vitamin A deficiency contributed to the risk of perinatal

transmission.9 Studies are testing a vitamin A supplementation

program, which would be practical and inexpensive in resource-poor

settings.Breastfeeding The benefits of breastfeeding are well

established. It promotes development of a newborn's gastrointestinal

and immune systems and, by enhancing immunity, lowers the risk of

diseases such as meningitis and infections of the respiratory system.

Breastfeeding protects babies from diarrhea, the major cause of

infant death in developing countries, and provides excellent

nutrition without potential infection from unclean water. It also

benefits the mother, including a more rapid postpartum recovery and

a reduction in breast cancer risk. Finally, breastfeeding is a key

component of the lactational amenorrhea method (LAM) of pregnancy

prevention.



However, studies have shown conclusively that breastmilk transmits

HIV. A review of four studies of women who acquired HIV infection

postnatally estimated the risk of transmission through breastfeeding

at 29 percent. The same review analyzed five studies in which the

mother was infected prenatally and found an additional risk of

transmission through breastfeeding, over and above transmission in

utero or during delivery, to be 14 percent.10  Several models have

sought to determine whether a change from breastfeeding to

bottlefeeding would result, on balance, in a higher or lower child

mortality. The models weighed the risk of HIV infection against the

risk of dying from diarrhea and other infections.11  The models

suggest different breastfeeding policies for three different

settings. Most models conclude that for places where infant

mortality, HIV prevalence and mortality from bottlefeeding are all

high, any change from breastfeeding to bottlefeeding would harm a

child's prospects for survival.In affluent, industrialized countries,

where bottlefeeding has little adverse effect on child mortality,

bottlefeeding by known HIV-infected mothers can increase child

survival.



In intermediate settings, the appropriate policy is not clear. In

1992, WHO and the United Nations Children's Fund (UNICEF) considered

relative risks carefully in making recommendations for these

intermediate settings. Where other infectious diseases and

malnutrition are primary causes of infant deaths, the recommendations

say, "breastfeeding should remain the standard advice to pregnant

women, including those who are known to be HIV-infected, because

their baby's risk of becoming infected through breastmilk is likely

to be lower than its risk of dying of other causes if deprived of

breastfeeding."12  Few developing countries are prepared to provide

universal HIV testing for pregnant women. One exception is Thailand,

where such testing occurs in some areas. "Women identified as

HIV-infected in early pregnancy are advised to seek a termination,

those identified in later pregnancy are told to bottlefeed and given

supplies of breastmilk substitutes," report Dr. Angus Nicoll of the

Communicable Disease Surveillance Centre in London and colleagues.13

Voluntary HIV counseling and testing can give pregnant women the

information they need to make an informed decision about their

current pregnancy and future childbearing.



-- William R. Finger

References



1 Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV and infant

feeding: An interim statement. Wkly Epidemiol Record 1996;71:289-91.



2 Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,

zidovudine treatment, and the risk of transmission of human

immunodeficiency virus type 1 from mother to infant. N Engl J Med

1996;335(22):1621-29; Mandelbrot L, Mayaux M-J, Bongain A, et al.

Obstetric factors and mother-to-child transmission of human

immunodeficiency virus type 1: The French perinatal cohorts. Am J

Obstet Gynecol 1996;175(3):661-7; Landesman SH, Kalish LA, Burns DN,

et al. Obstetrical factors and the transmission of human

immunodeficiency virus type 1 from mother to child. N Engl J Med

1996;334(25):1617-23; St. Louis ME, Kamenga M, Brown C, et al. Risk

for perinatal HIV-1 transmission according to maternal immunologic,

virologic, and placental factors. JAMA 1993;269(22):2853-59.



3 Zidovudine for the prevention of HIV transmission from mother to

infant. MMWR 1994;43:285-7.



4 Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076:

The changing pattern of zidovudine use during pregnancy, and the

subsequent reduction in the vertical transmission of human

immunodeficiency virus in a cohort of infected women and their

infants. J Infect Dis 1996;174:1207-11.



5 Bulterys M, Chao A, Dushimimana A, et al. Fatal complications after

Cesarian section in HIV-infected women. AIDS 1996; 10(8):923-4;

Semprini AE, Castagna C, Ravizza M, et al. The incidence of

complications after caesarean section in 156 HIV-positive women. AIDS

1995;9:913-7.



6 Landesman.



7 Landers D, Sweet R. Reducing mother-to-infant transmission of HIV

-- the door remains open. N Engl J Med 1996;334(25):1664-5. 



8 Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial

in Africa: Effect of a birth canal cleansing intervention to prevent

HIV transmission. Lancet 1996; 347:1647-50.



9 Semba RD, Miotti PG, Chiphangwi JD, et al.  Maternal vitamin A

deficiency and mother-to-child transmission of HIV-1. Lancet

1994;343:1593-7



10 Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency

virus type 1 transmission through breastfeeding. Lancet

1992;340:585-8.



11 Nicoll A, Newell M-L, Van Praag E, et al. Editorial review: Infant

feeding policy and practice in the presence of HIV-1 infection. AIDS

1995;9:107-19; Kennedy KI, Fortney JA, Bonhomme MG, et al. Do the

benefits of breastfeeding outweigh the risk of potential transmission

of HIV via breastmilk? Trop Doct 1990;20:25-29.



12 Consensus Statement from the WHO/UNICEF Consultation on HIV

Transmission and Breastfeeding, Geneva 30 April-1 May, 1992.



13  Nicoll.





Copyright 1997, Family Health International.  Any part of this text

may be copied, reproduced, distributed or adapted without permission

from the authors or publisher, provided that the recipient of this

text may not copy, reproduce, distribute or adapt this text for

commercial gain, and provided further that Family Health

International is credited as the source of such information on all

copies, reproductions, distributions and adaptations of this text.



All questions and comments should be sent to:



Postmaster

Family Health International

P.O. Box 13950

Research Triangle Park, NC 27709

USA



telephone: (919) 544-7040




















For further information, please contact: popin@undp.org
POPIN Gopher site: gopher://gopher.undp.org/11/ungophers/popin
POPIN WWW site:http://www.undp.org/popin